Key Points
- Director Troy Cox purchased 15,620 Maplight Therapeutics shares at an average price of $9.52, investing approximately $148,702 and taking his ownership to 15,620 shares.
- Maplight’s Phase 2 ZEPHYR trial succeeded for the twice-daily 210/3 mg dose in schizophrenia, but the once-daily arm failed; the company plans another trial before seeking registration.
- The stock traded at $12.31 after a reported 24.3% gain, while analysts maintained an overall “Buy” consensus despite sharply reduced price targets and the company’s quarterly loss exceeding expectations.
Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) Director Troy Cox acquired 15,620 shares of Maplight Therapeutics stock in a transaction dated Tuesday, July 28th. The shares were bought at an average cost of $9.52 per share, with a total value of $148,702.40. Following the completion of the purchase, the director owned 15,620 shares in the company, valued at approximately $148,702.40. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Maplight Therapeutics Trading Up 24.3%
NASDAQ MPLT opened at $12.31 on Wednesday. Maplight Therapeutics, Inc. has a 1 year low of $9.10 and a 1 year high of $40.43. The company has a market cap of $524.65 million and a PE ratio of -0.30. The stock's 50-day moving average price is $31.54 and its two-hundred day moving average price is $25.00.
Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last announced its earnings results on Thursday, May 14th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.43). Research analysts forecast that Maplight Therapeutics, Inc. will post -5.13 EPS for the current fiscal year.
Trending Headlines about Maplight Therapeutics
Here are the key news stories impacting Maplight Therapeutics this week:
- Positive Sentiment: The ZEPHYR trial met its primary endpoint for the 210/3 mg twice-daily dose, which produced a statistically significant improvement in PANSS total score versus placebo. The dose also showed benefits on cognition, symptom severity and positive symptoms, with generally favorable tolerability. MapLight plans another potentially registrational trial and an FDA End-of-Phase 2 meeting. MapLight Announces Positive Topline Results
- Positive Sentiment: Analysts still see potential value after the selloff. HC Wainwright retained a “buy” rating with a $26 price target, while Morgan Stanley maintained “equal weight” with a $21 target—both above the recent trading level, although each firm reduced its target substantially. Analyst Rating Reports
- Neutral Sentiment: The twice-daily regimen’s success may preserve a development path for ML-007C-MA, but the results are not yet sufficient for approval. MapLight expects to conduct another trial to replicate the findings before pursuing registration.
- Negative Sentiment: The key disappointment was the once-daily dosing arm, which failed to show statistically significant symptom improvement. Investors viewed this as a major setback because a once-daily treatment could have offered a simpler, more convenient option. The news erased more than $1 billion in market value and sharply reduced confidence in the program. MapLight Once-Daily Trial Report
- Negative Sentiment: A law firm has announced an investor fraud investigation opportunity related to MapLight. The notice does not establish wrongdoing, but such announcements can add legal and reputational uncertainty to an already volatile stock. Investor Fraud Investigation Notice
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Strs Ohio bought a new position in shares of Maplight Therapeutics in the 4th quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Maplight Therapeutics in the fourth quarter valued at approximately $70,000. New York State Common Retirement Fund bought a new stake in shares of Maplight Therapeutics during the 4th quarter worth $93,000. MetLife Investment Management LLC bought a new stake in shares of Maplight Therapeutics during the 4th quarter worth $172,000. Finally, Walleye Capital LLC acquired a new position in Maplight Therapeutics during the 4th quarter worth $205,000.
Analyst Upgrades and Downgrades
MPLT has been the topic of several research analyst reports. Jefferies Financial Group reaffirmed a "buy" rating on shares of Maplight Therapeutics in a research note on Monday. UBS Group boosted their price objective on shares of Maplight Therapeutics from $48.00 to $52.00 and gave the company a "buy" rating in a research report on Tuesday, July 21st. Canaccord Genuity Group cut their target price on shares of Maplight Therapeutics from $43.00 to $24.00 and set a "buy" rating for the company in a research report on Tuesday. TD Cowen initiated coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They set a "buy" rating for the company. Finally, Craig Hallum reissued a "buy" rating and set a $25.00 price objective on shares of Maplight Therapeutics in a research report on Tuesday. Four equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $34.42.
Read Our Latest Analysis on MPLT
Maplight Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
